INOVIQ Ltd Annual Report 2022

22 INOVIQ Limited Directors’ Report The directors present their report together with the financial report of INOVIQ Limited (INOVIQ or the Company) and its controlled entities (collectively referred to as the Group) for the financial year ended 30 June 2022 and the independent auditor’s report thereon. PRINCIPAL ACTIVITIES The principal activities of the Group are the development and commercialisation of an innovative portfolio of diagnostic and exosome-based products to improve the diagnosis and treatment of cancer and other diseases. The Group has commercialised the EXO-NET® pan-exosome capture tool for research purposes and the hTERT test as an adjunct to urine cytology testing for bladder cancer. INOVIQ’s cancer diagnostic pipeline includes blood tests in development for earlier detection and monitoring of ovarian, breast and other cancers. CORPORATE INFORMATION INOVIQ Limited is a Company limited by shares and is incorporated and domiciled in Australia. It is the ultimate legal parent entity of the INOVIQGroup. As at 30 June 2022 it had two wholly owned subsidiaries, Sienna Cancer Diagnostics Ltd (an Australian public company) and BARD1AG SA (a company domiciled in Switzerland). INOVIQ Inc (a US entity) forms part of the group, being a 100% owned subsidiary of Sienna Cancer Diagnostics Ltd. DIRECTORS The names and details of the directors of the Company in office during the year ended 30 June 2022 and until the date of this report are as follows (Directors were in office for this entire period unless otherwise stated): Dr Geoffrey Cumming BSc (Hons) BAppSc PhDMBAMAICD | Non-ExecutiveChairman (appointed 28 July 2020) Dr Cumming has held senior roles in the global healthcare and biotechnology sector for more than 20 years. As Managing Director, Roche Diagnostic Systems (Oceania), Dr Cumming transformed the loss-making entity the Swiss parent was intending to divest, into the fastest growing and most profitable affiliate in the Roche group. In his role as Managing Director/ CEO of Biosceptre International Ltd, Dr Cumming was successful in designing and securing key funding arrangements through a skilful range of capital raising initiatives, including large government grants, partnering and co-development deals. His most recent executive role was as Managing Director / CEO of Anteo Diagnostics Ltd (ASX: ADO). He is currently a Non-executive Director of Anteo Diagnostics Ltd and was previously Chairman of Sienna Cancer Diagnostics Ltd and a Nonexecutive Director of Medical Australia Ltd (ASX: MLA). Dr Cumming is the Chair of the Remuneration Committee. Dr Cumming has not been a director of any listed companies in the last three years other than those listed above. Mr Robert (Max) Johnston | Non-Executive Director (appointed 17 June 2019) Mr Johnston held the position of President and Chief Executive Officer of Johnson & Johnson Pacific, a division of the world’s largest medical, pharmaceutical and consumer healthcare company for 11 years. Prior to joining Johnson & Johnson, Mr Johnston’s career also included senior roles with Diageo and Unilever in Australia, Africa, and Europe. Mr Johnston has also held several prominent industry roles as a past President of ACCORD Australasia Limited, a former Vice Chairman of the Australian Food and Grocery Council and a former member of the board of the Australian Skills Management Institute (ASMI). Mr Johnston has had extensive overseas experience during his career in leading businesses in bothWestern and Central‑Eastern Europe and Africa as well as the Asia-Pacific region. Mr Johnston is currently a Non-Executive Director of Medical Developments International Ltd (ASX: MVP) and Tissue Repair Ltd (ASX: TRP). He was a former Non‑Executive Director of Enero Group Limited (ASX: EGG) and PolyNovo Ltd (ASX: PNV), and a former Non‑Executive Chairman of Probiotec Ltd (ASX: PBP) and AusCann Group Holdings Ltd (ASX: AC8). Mr Johnston is a member of the Company’s Remuneration and Audit & Risk Committees. Mr Johnston has not been a director of any listed companies in the last three years other than those listed above. Mr Philip Powell BComm (Hons) ACAMAICD | Non-Executive Director (appointed 17 June 2019) Mr Powell is a Chartered Accountant with extensive experience in investment banking, specialising in capital raisings, initial public offerings (IPOs), mergers and acquisitions and other successful corporate finance assignments across a diverse range of sectors including pharma, utilities, IT, financial services, food, and agriculture. He spent 10 years in senior financial roles at OAMPS Ltd, a former ASX-listed financial services group, and 10 years in audit with Arthur Andersen & Co inMelbourne, Sydney, and Los Angeles. Mr Powell is currently a Non-Executive Director of RMA Global Ltd (ASX: RMY). He was a former Non- Executive Director of PolyNovo Ltd (ASX: PNV) andMedical Developments International Ltd (ASX: MVP). Mr Powell is the Chair of the Company’s Audit & Risk Committee. Mr Powell has not been a director of any listed companies in the last three years other than those listed above.

RkJQdWJsaXNoZXIy MjE2NDg3